Risen (Suzhou) Pharma Tech Co., Ltd.

Neurochem (International) Limited

Bhi Limited Partnership

Queen's University at Kingston

Bellus Health Inc.

Shanghai Junshi Biosciences Co., Ltd.

Other

Bellus Health (International) Limited

Shanghai Junshl Biosciences Co., Ltd.

Neurochem, Inc.

Xianqi Kong

Jiamin Gu

Jiasheng Lu

David Migneault

Xinfu Wu

Xiang Ji

Walter A Szarek

Isabelle Valade

Abderrahim Bouzide

Daiqiang Hu

Daniel Delorme

Benoit Bachand

Sophie Levesque

Francine Gervais

Dongdong Wu

Mohamed Atfani

Gang Chen

Xiuchun Zhang

Stephane Ciblat

Xinyong Lv

Lin Wang

Dongqing Zhu

Jinchao Ai

Xiaolin He

Donald F Weaver

Feng Zhou

Ajay Gupta

Guowei Song

Jun Gu

Xiaolin Zhang

Nigel Levens

Bita Samim

Richard Frenette

Robert Kisilevsky

Gregory R J Thatcher

Serge Lamothe

Stéphane Ciblat

Robert Chalifour

Lucie Jetté

Boris I Gorine

Qiguo Zhang

Xuli Wang

Jinchao Al

Chengyong Sun

Paul Fraser

Mohammed Atfani

Johanne Renaud

There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease.RRX—CR—CH—CH—SOH   (I)

Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereof

There are provided methods for treating or preventing a cerebrovascular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an isotope-enriched compound or a pharmaceutical composition thereof, where the isotope-enriched compound has the general Formula (I) or is a pharmaceutically acceptable salt or ester thereof:RRX—CR—CH—CH—SOH  (I).

Isotope-enriched 3-amino-1-propanesulfonic acid derivatives for the treatment of cerebrovascular disease

There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.

Stable heavy isotopes in amide functional groups and uses thereof

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a manual of joint and bone disorders such as arthritis and osteoporosis.

Glucosamine derivatives for the prevention or treatment of joint disorders

There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.

Prodrugs of a CDK inhibitor for treating cancers

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.

The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.

Crystalline form of 3-((L-valyl) amino))-3, 3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis. 

Glucosamine derivatives and pharmaceutical uses thereof

CD73 (also known as ecto-5'-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof. 

CD73 inhibitors and pharmaceutical uses thereof

There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers. 

Crystalline form of 3-((L-valyl)amino))-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-&#x3b2; related diseases, such as Alzheimer's disease.RRX&#x2014;CR&#x2014;CH&#x2014;CH&#x2014;SOH&#x2003;&#x2003;(I)

Growing community of inventors

Dollard-des-Ormeaux, Canada

Xianqi Kong